Search results
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
Benzinga· 5 days agoFollowing the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (Day 180) after ...
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data...
Benzinga· 4 days agoFollowing the initial analysis up to Day 29 post-vaccination, the most recent analysis of study...
Eisai Starts Rolling Submission for Injectable Version of Alzheimer's Drug With US FDA
US News & World Report· 3 days agoThe companies are seeking the Food and Drug Administration's (FDA) approval of a weekly dose of Leqembi to be given as an under-the-skin injection. Under a rolling submission the regulator assesses ...
Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren’s syndrome in...
Nature· 4 days agoPrimary Sjögren’s syndrome (pSS) is a chronic inflammatory autoimmune disease with an unclear pathogenesis, and there is currently no approved drug for the treatment of this disease. Iguratimod ...
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel...
WPRI Providence· 7 days agoReplicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology, autoimmune disease indications ...
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive...
Benzinga· 19 hours agoCelltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients with moderately to severely active Crohn's ...
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Zacks via Yahoo Finance· 2 days agoBiogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA...
Q1 2024 Vaxart Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 3 days agoNorovirus causes an estimated 50,000 child deaths every year, mostly in developing countries. As a reminder, this was a Phase 1 multicenter, randomized, double-blind placebo controlled, dose ...
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
NewMediaWire via Yahoo Finance· 3 days agoPresented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
The Yuma Sun· 3 days agoExpanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors
